MHE is a rare genetic disorder characterized by multiple benign bone tumors (osteochondromas), leading to deformities, pain, and restricted mobility in severe cases. Growing awareness of MHE and hereditary conditions is expected to act as a driver for market growth. Although, advanced therapies like palovarotene are associated with significant annual costs, rendering effective treatment inaccessible for many patients, especially those lacking sufficient insurance coverage. This is expected to act as a restraint on market growth.
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PIPELINE ANALYSIS - OBSERVATORY DATA
4.4 EPIDEMIOLOGY
5 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: REGULATIONS
5.1 REGULATION IN UNITED STATES: U.S. FOOD AND DRUG ADMINISTRATION (FDA)
5.1.1 REGULATION IN EUROPE: EUROPEAN MEDICINES AGENCY (EMA)
5.2 REGULATION IN ASIA-PACIFIC (JAPAN): PHARMACEUTICAL AND MEDICAL DEVICES AGENCY (PMDA)
5.3 MEDICAL DEVICE STANDARDS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF GENETIC DISORDERS
6.1.2 GROWING PEDIATRIC POPULATION
6.1.3 DEVELOPMENT OF NOVEL THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST OF ADVANCED THERAPIES
6.2.2 LIMITED AVAILABILITY OF THERAPIES
6.3 OPPORTUNITIES
6.3.1 INCREASE IN PATIENT CARE AND SUPPORT SYSTEMS
6.3.2 INCREASE IN THE NUMBER OF COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 LIMITED AWARENESS ABOUT THE DISORDER
6.4.2 LACK OF DRUG APPROVALS ASSOCIATED WITH THE DISORDER
7 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE
7.1 OVERVIEW
7.2 SESSILE
7.3 PEDUNCULATED
8 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY
8.2.1 REMOVE THE TUMOR
8.2.2 LENGTHEN LIMBS
8.3 MEDICATION
8.3.1 HOSPITAL PHARMACIES
8.3.2 DRUGS STORES AND RETAIL PHARMACIES
8.3.3 ONLINE PHARMACIES
8.4 OTHERS
9 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 X-RAY
9.2.1 SESSILE
9.2.2 PEDUNCULATED
9.3 COMPUTED TOMOGRAPHY (CT) SCAN
9.3.1 SESSILE
9.3.2 PEDUNCULATED
9.4 MAGNETIC RESONANCE IMAGING (MRI)
9.4.1 SESSILE
9.4.2 PEDUNCULATED
9.5 GENETIC TESTS
9.5.1 SESSILE
9.5.2 PEDUNCULATED
9.6 OTHERS
9.6.1 SESSILE
9.6.2 PEDUNCULATED
10 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE
10.1 OVERVIEW
10.2 LEGS
10.3 ARMS
10.4 SHOULDERS
10.5 PELVIS
10.6 FINGERS
10.7 TOES
11 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 PEDIATRIC
11.3 ADULT
12 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.2.1 PRIVATE
12.2.2 GOVERNMENT
12.3 SPECIALTY CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 MIDDLE EAST AND AFRICA MULTIPLE HEREDITY EXOSTOSIS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SAUDI ARABIA
13.1.2 U.A.E.
13.1.3 EGYPT
13.1.4 KUWAIT
13.1.5 QATAR
13.1.6 OMAN
13.1.7 BAHRAIN
13.1.8 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 BAYERS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT UPDATES
16.2 HALEON GROUP OF COMPANIES
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BASF
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT UPDATES
16.4 VIATRIS INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT UPDATES
16.5 ACTIZAPHARMA
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT UPDATES
16.6 ADVACARE PHARMA
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT UPDATES
16.7 AUROBINDO PHARMA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT TABLETS
16.8 HALEON GROUP OF COMPANIES
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT UPDATES
16.9 IPSEN BIOPHARMACEUTICALS, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT UPDATES
16.1 MALLINCKRODT
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT UPDATES
16.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT UPDATES
16.12 TAJ PHARMACEUTICALS LIMITED
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT UPDATES
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 PIPELINE ANALYSIS - OBSERVATORY DATA
TABLE 2 PIPELINE ANALYSIS - INTERVENTIONAL DATA
TABLE 3 SALES DATA - 2024
TABLE 4 SALES DATA - 2023
TABLE 5 SALES DATA - 2022
TABLE 6 SALES DATA - 2021
TABLE 7 SALES DATA - 2020
TABLE 8 SALES DATA - 2019
TABLE 9 SALES DATA - 2018
TABLE 10 COST OF PALOVAROTENE
TABLE 11 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA SESSILE IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA PEDUNCULATED IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA LEGS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA ARMS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA SHOULDERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA PELVIS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA FINGERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA TOES IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA PEDIATRIC IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA ADULT IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 64 SAUDI ARABIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 SAUDI ARABIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 66 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 67 SAUDI ARABIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 SAUDI ARABIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 SAUDI ARABIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 SAUDI ARABIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 SAUDI ARABIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 73 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 74 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 75 SAUDI ARABIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 SOUTH AFRICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 SOUTH AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 80 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 81 SOUTH AFRICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 SOUTH AFRICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 SOUTH AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 SOUTH AFRICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 SOUTH AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 87 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 88 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 89 SOUTH AFRICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 92 U.A.E. SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 U.A.E. MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 94 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 95 U.A.E. X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.A.E. COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 U.A.E. MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 U.A.E. GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 U.A.E. OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 101 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 102 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 103 U.A.E. HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 106 EGYPT SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 107 EGYPT MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 108 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 109 EGYPT X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 EGYPT COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 EGYPT MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 EGYPT GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 EGYPT OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 114 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 115 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 116 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 117 EGYPT HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 120 KUWAIT SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 KUWAIT MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 122 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 123 KUWAIT X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 KUWAIT COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 KUWAIT MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 126 KUWAIT GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 127 KUWAIT OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 128 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 129 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 130 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 131 KUWAIT HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 134 QATAR SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 QATAR MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 136 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 137 QATAR X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 QATAR COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 QATAR MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 QATAR GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 QATAR OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 143 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 144 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 145 QATAR HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 146 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 148 OMAN SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 OMAN MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 150 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 151 OMAN X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 OMAN COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 OMAN MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 OMAN GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 OMAN OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 156 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 157 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 158 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 159 OMAN HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 162 BAHRAIN SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 163 BAHRAIN MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 164 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 165 BAHRAIN X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 BAHRAIN COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 BAHRAIN MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 BAHRAIN GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 BAHRAIN OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 170 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 171 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 172 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 173 BAHRAIN HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 174 REST OF MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 PRODUCT LIFELINE CURVE
FIGURE 9 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA MULTIPLE HEREDITY EXOSTOSIS MARKET, BY TYPE
FIGURE 15 RISING PREVALENCE OF GENETIC DISORDERS IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET FROM 2024 TO 2031
FIGURE 16 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET IN 2024 AND 2031
FIGURE 17 MARKET OVERVIEW
FIGURE 18 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2023
FIGURE 19 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 20 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2023
FIGURE 23 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 24 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 25 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2023
FIGURE 27 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2024-2031 (USD THOUSAND)
FIGURE 28 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, CAGR (2024-2031)
FIGURE 29 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2023
FIGURE 31 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2024-2031 (USD THOUSAND)
FIGURE 32 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, CAGR (2024-2031)
FIGURE 33 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2023
FIGURE 35 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 36 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 37 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2023
FIGURE 39 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 40 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 41 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 MIDDLE EAST AND AFRICA MULTIPLE HEREDITY EXOSTOSIS MARKET: SNAPSHOT (2023)
FIGURE 43 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY SHARE 2023 (%)
